[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@doctorvasan](/creator/twitter/doctorvasan)
"Statins' secret sauce: Aggressive LDL-C guidelines evolved from XXX mg/dL targets in the '80s to XX for high-risk by 2004 (AHA/ACC). Result Usage exploded Sales peaked at $35.3B globally in '09 with Lipitor hitting $13B/yr solo. Awareness + access = goldmine"  
[X Link](https://x.com/doctorvasan/status/1981713281656951000) [@doctorvasan](/creator/x/doctorvasan) 2025-10-24T13:23Z 1487 followers, XX engagements


"Obicetrapib =Statin XXX Ever wondered why statins became a $35B+ global juggernaut in 2009 Blockbuster LDL-C lowering met exploding awareness of heart disease risks. Now enter obicetrapib $NAMS poised to eclipse that trajectory in a smarter hungrier market. 🧵"  
[X Link](https://x.com/doctorvasan/status/1981713278377058364) [@doctorvasan](/creator/x/doctorvasan) 2025-10-24T13:23Z 1487 followers, XX engagements


"Fast-forward to 2025: Guidelines got TOUGHER. ESC/EAS 2025 mandates XX mg/dL for very high-risk (ASCVD) XX for recurrent events. AACE echoes: XX for high-risk but "lower for longer is better"no floor at XX mg/dL. NLA pushes combo therapy for extreme cases (30 mg/dL)"  
[X Link](https://x.com/doctorvasan/status/1981713285914251637) [@doctorvasan](/creator/x/doctorvasan) 2025-10-24T13:24Z 1487 followers, XXX engagements


"45%. 3) The recent VESUVIUS C trial reinforceslower the better mantra for LDLc that has been gaining ground in Lipidology/Cardiology for several years & guidelines will start reflecting it. Put it all together & the rationale for adding Obi to statin becomes overwhelming"  
[X Link](https://x.com/doctorvasan/status/1981713311394828776) [@doctorvasan](/creator/x/doctorvasan) 2025-10-24T13:24Z 1487 followers, XX engagements


"Add in the AD premium that alone is worth $15B+ by 2030. Upside Massive. Sales math: Statins stabilized at $15-17B today (generics crushed prices but volume up). Obicetrapib projections Wells Fargo: $3.5B peak US + $450M EU royalties (Menarini deal)"  
[X Link](https://x.com/doctorvasan/status/1981713314926530654) [@doctorvasan](/creator/x/doctorvasan) 2025-10-24T13:24Z 1487 followers, XX engagements


"GlobalData: $1.4B in 7MM by '32. Conservative Nahadd Lp(a)/DM/AD labels and it's $5B+ peak easy. EMA MAA validated; US launch late XX. Historical parallel: Lipitor launched '97 into a $1B market; hit $13B peak by '06 on guideline shifts + marketing. Obicetrapib enters a $20B+"  
[X Link](https://x.com/doctorvasan/status/1981713318705246300) [@doctorvasan](/creator/x/doctorvasan) 2025-10-24T13:24Z 1488 followers, XX engagements